Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology

Partnership Agreement:
Neomorph and AbbVie have entered a collaboration and option-to-license agreement to develop molecular glue degraders for multiple targets across oncology and immunology14.

Financial Terms:
Neomorph will receive an upfront payment from AbbVie and is eligible to receive up to $1.64 billion in aggregate option fees and milestones, as well as tiered royalties on net sales14.

Molecular Glue Degraders:
These are a novel class of small molecules designed to selectively target and trigger degradation of proteins that drive cancer growth or immune system dysregulation4.

Target Areas:
The collaboration focuses on developing treatments for oncology and immunology, aiming to tackle historically "undruggable" targets4.

Neomorph’s Expertise:
Neomorph has a leading molecular glue discovery platform and a team of industry-leading experts in protein degradation and molecular glues4.

AbbVie’s Commitment:
AbbVie is committed to advancing protein degrader technology and sees this collaboration as a way to develop new, effective therapies for immune disorders and cancer4.

Sources:

1. https://www.dcatvci.org/top-industry-news/global-briefs-sanofi-abbvie-more/

4. https://www.prnewswire.com/news-releases/abbvie-and-neomorph-announce-collaboration-to-develop-molecular-glue-degraders-for-oncology-and-immunology-302357741.html